Abstract:Stroke is the leading cause of death and disability in ageing individuals. Previous epidemiological investigations and basic studies have demonstrated that estrogen replacement therapy exerted neuroprotective effects against stroke in menopausal women and ovariectomised (OVX) animals. The underlying mechanism remains unclear. ndrg2 is a new gene cloned in 2001 related to cell proliferation and differentiation, and stress responses. Our previous studies found that ndrg2 is specifically expressed in astrocytes in the brain and played an important role in cerebral ischaemic injury. However, the role of ndrg2 in estrogen neuroprotection against cerebral ischaemia has not been reported. In in vivo experiments, adult female C57 mice and ndrg2 gene knockout (ndrg2–/–) female mice were OVX and 7 days later treated with 50 μg kg–1 17β-estradiol (E2), 100 μg kg–1 E2, 2 mg kg–1 ERα agonist (PPT), or 8 mg kg–1 ERβ agonist (DPN) for 14 days. We detected the expression of ndrg2 mRNA and protein in brain tissue using real-time polymerase chain reaction (PCR), western blot, and immunofluorescence double labelling. We constructed a middle cerebral artery occlusion (MCAO) ischaemia model, and we also measured the expression of ndrg2 mRNA and protein at different times after reperfusion in the ischaemic penumbra. Triphenyltetrazolium chloride (TTC) staining was used to determine the ischaemic injury. In in vitro experiments, primary cultured astrocytes received E2, DPN, and PPT treatment. Real-time PCR and western blot were used to detect the expression of astrocyte ndrg2 mRNA and protein. We constructed an oxygen and glucose deprivation (OGD) model, and detected the expression of astrocyte ndrg2 mRNA and protein at different times after OGD. E2 or DPN treatment significantly up-regulated the expression of ndrg2 mRNA and protein in primary astrocytes and in the brain of OVX female. Expression of ndrg2 mRNA and protein in the ischaemic penumbra region after cerebral ischaemia was significantly increased 6 h after reperfusion and peaked at 24 h with nuclear translocation. Expression of ndrg2 mRNA and protein in primary astrocytes after OGD injury was significantly increased at 2 h after reoxygenation and peaked at 6 h also with nuclear translocation. ndrg2–/– female mice exhibited significantly larger infarct volume than ndrg2+/+ female mice. E2 or DPN replacement therapy significantly reduced infarct volume in ndrg2+/+-OVX female mice, but 50 μg kg–1 E2 or 8 mg kg– DPN replacement therapy did not significantly reduce infarct volume in ndrg2–/–-OVX female mice. Our study found that astrocyte ndrg2 is a target gene for estrogen and ERβ, and that estrogen or DPN replacement treatment significantly reduced cerebral ischaemia injury in OVX mice. Astrocyte ndrg2 is the key molecule mediating the neuroprotective effects of estrogen and ERβ against cerebral ischaemia and provides a potential new molecular target for estrogen neuroprotection.

The Loss of Estrogen Efficacy Against Cerebral Ischemia in Aged Postmenopausal Female Mice

Loss of Estrogen Efficacy Against Hippocampus Damage in Long-Term OVX Mice Is Related to the Reduction of Hippocampus Local Estrogen Production and Estrogen Receptor Degradation

Impact of estradiol deficiency on immune system in young and aged mice

Pretreatment with 17β-Estradiol Attenuates Cerebral Ischemia-Induced Blood-Brain Barrier Disruption in Aged Rats: Involvement of Antioxidant Signaling

The Effects of Different Doses of Estradiol (E2) on Cerebral Ischemia in an in Vitro Model of Oxygen and Glucose Deprivation and Reperfusion and in a Rat Model of Middle Carotid Artery Occlusion.

Abstract 14875: Estrogen-Induced Vasoprotection is Preserved after Prolonged Estrogen Deprivation

Estrogen-receptor-mediated protection of cerebral endothelial cell viability and mitochondrial function after ischemic insult in vitro.

Estrogen deficiency is associated with hippocampal morphological remodeling of early postmenopausal mice.

Ndrg2: a Novel Target for Estrogen Neuroprotection Against Cerebral Ischaemia

Estrogen Deficiency Induces Mitochondrial Damage Prior to Emergence of Cognitive Deficits in a Postmenopausal Mouse Model

CB1 agonism prolongs therapeutic window for hormone replacement in ovariectomized mice.

Estrogen inhibits Fas-mediated apoptosis in experimental stroke.

Estrogen replacement therapy-induced neuroprotection against brain ischemia-reperfusion injury involves the activation of astrocytes via estrogen receptor β

Long-term estrogen deprivation leads to elevation of Dickkopf-1 and dysregulation of Wnt/β-Catenin signaling in hippocampal CA1 neurons

Brain Endogenous Estrogen Levels Determine Responses to Estrogen Replacement Therapy via Regulation of BACE1 and NEP in Female Alzheimer’s Transgenic Mice

The aging ovary impairs acute stroke outcomes

Increased Vulnerability of Brain to Estrogen Withdrawal-Induced Mitochondrial Dysfunction with Aging.

Genistein Attenuates Brain Damage Induced by Transient Cerebral Ischemia Through Up-Regulation of ERK Activity in Ovariectomized Mice.

Protective Effects of 17Β-Estradiol on Hippocampal Myelinated Fibers in Ovariectomized Middle-aged Rats.

C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-α and the critical period hypothesis of estrogen neuroprotection

The cognitive rehabilitation of acute estrogen treatment after focal brain ischemia in adult rats